These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27628195)

  • 21. Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Kishimoto J; Uchino K; Arita S; Kumagai H; Mitsugi K; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):29-34. PubMed ID: 23228984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
    Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
    Park SR; Kong SY; Rhee J; Park YI; Ryu KW; Lee JH; Kim YW; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim NK
    Ann Oncol; 2011 Apr; 22(4):890-896. PubMed ID: 20860988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
    Takii Y; Yamazaki T; Okada T; Tani T; Funakoshi K; Maruyama S; Hasegawa J; Akazawa K; Hatakeyama K;
    Chemotherapy; 2013; 59(5):338-43. PubMed ID: 24820531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
    Ishihara S; Matsusaka S; Kondo K; Horie H; Uehara K; Oguchi M; Murofushi K; Ueno M; Mizunuma N; Shinbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Nakajima T; Watanabe T
    Radiat Oncol; 2015 Jan; 10():24. PubMed ID: 25612635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
    Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
    Said R; Kurzrock R; Naing A; Hong DS; Fu S; Piha-Paul SA; Wheler JJ; Janku F; Kee BK; Bidyasar S; Lim J; Wallace M; Tsimberidou AM
    Invest New Drugs; 2015 Aug; 33(4):911-20. PubMed ID: 25990659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
    Goya H; Kuraishi H; Koyama S; Ichiyama T; Yoshiike F; Hirai K; Agatsuma T; Tateishi K; Kanda S; Yamamoto H; Kubo K; Koizumi T
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):691-7. PubMed ID: 22941346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
    Mabuchi S; Yokoi E; Owa T; Kozasa K; Yamashita M; Kobayashi E; Tomimatsu T; Yoki T; Tsutui T; Kimura T
    Int J Gynecol Cancer; 2016 Sep; 26(7):1281-7. PubMed ID: 27643650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
    Ford HE; Cunningham D; Ross PJ; Rao S; Aherne GW; Benepal TS; Price T; Massey A; Vernillet L; Gruia G
    Br J Cancer; 2000 Jul; 83(2):146-52. PubMed ID: 10901362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
    Jeung HC; Rha SY; Cho BC; Yoo NC; Roh JK; Roh WJ; Chung HC; Ahn JB
    Br J Cancer; 2006 Dec; 95(12):1637-41. PubMed ID: 17106441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
    Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
    Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
    Sato T; Kokuba Y; Koizumi W; Hayakawa K; Okayasu I; Watanabe M
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1442-7. PubMed ID: 17855009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
    Kim SY; S Hong Y; K Shim E; Kong SY; Shin A; Baek JY; Jung KH
    Br J Cancer; 2013 Sep; 109(6):1420-7. PubMed ID: 23963147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).
    Komatsu Y; Takahashi Y; Kimura Y; Oda H; Tajima Y; Tamura S; Sakurai J; Wakasugi T; Tatebe S; Takahashi M; Sakata Y; Kitajima M; Sakamoto J; Saji S
    Anticancer Drugs; 2011 Jul; 22(6):576-83. PubMed ID: 21512394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.